Replies to post #17141 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Greer discovered that AMPA modulators could impact RD via the Pre-Botzinger complex, and thus patented the use of AMPA modulation for that purpose. Cortex owns CX717, but would not be able to market it for the RD use without a license from U.Alberta. They now have both the molecule, and an exclusive license for the RD use. I recall a small upfront payment ($250K?), I'm sure there will be milestones and small (typically 2-3%) royalties.

NeuroInvestment

[K-G]

The University of Alberta apparantly holds or has applied for a patent for the use of ampakines in treating respiratory depression. (I tried to search the US Patent and Trade Mark data base, but could not find it. Maybe someone else can.) Cortex in-licensed the rights to their use patent. The referenced article for respiratory depresson is at the link below.

http://ajrccm.atsjournals.org/cgi/content/full/174/12/1384